Global Markets Direct’s, Meniere Disease – Pipeline Review, H2 2016′, provides an overview of the Meniere Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report on Meniere Disease – Pipeline Review, H2 2016 addition with 18 market data tables and 11 figures, spread across 48 pages is http://www.rnrmarketresearch.com/meniere-disease-pipeline-review-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Drugs Profile Discussed in this Research:
betamethasone valerate ER, dexamethasone acetate SR, latanoprost, OR-105, QPHL-2, SPI-1005
Orbis Biosciences Inc , Otonomy, Inc.
Quark Pharmaceuticals, Inc.
Sound Pharmaceuticals, Inc.
Inquire before buying for this report
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=692214. (This is a premium report price at US$2000 for a single user PDF license).